1. Home
  2. MRNA vs NDSN Comparison

MRNA vs NDSN Comparison

Compare MRNA & NDSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRNA
  • NDSN
  • Stock Information
  • Founded
  • MRNA 2010
  • NDSN 1935
  • Country
  • MRNA United States
  • NDSN United States
  • Employees
  • MRNA N/A
  • NDSN N/A
  • Industry
  • MRNA Biotechnology: Biological Products (No Diagnostic Substances)
  • NDSN Industrial Machinery/Components
  • Sector
  • MRNA Health Care
  • NDSN Industrials
  • Exchange
  • MRNA Nasdaq
  • NDSN Nasdaq
  • Market Cap
  • MRNA 10.3B
  • NDSN 10.1B
  • IPO Year
  • MRNA 2018
  • NDSN N/A
  • Fundamental
  • Price
  • MRNA $30.28
  • NDSN $222.75
  • Analyst Decision
  • MRNA Hold
  • NDSN Strong Buy
  • Analyst Count
  • MRNA 19
  • NDSN 6
  • Target Price
  • MRNA $48.13
  • NDSN $258.33
  • AVG Volume (30 Days)
  • MRNA 9.3M
  • NDSN 478.3K
  • Earning Date
  • MRNA 07-31-2025
  • NDSN 08-20-2025
  • Dividend Yield
  • MRNA N/A
  • NDSN 1.40%
  • EPS Growth
  • MRNA N/A
  • NDSN N/A
  • EPS
  • MRNA N/A
  • NDSN 7.78
  • Revenue
  • MRNA $3,177,000,000.00
  • NDSN $2,704,444,000.00
  • Revenue This Year
  • MRNA N/A
  • NDSN $5.77
  • Revenue Next Year
  • MRNA $9.70
  • NDSN $4.99
  • P/E Ratio
  • MRNA N/A
  • NDSN $28.62
  • Revenue Growth
  • MRNA N/A
  • NDSN 1.98
  • 52 Week Low
  • MRNA $23.15
  • NDSN $165.03
  • 52 Week High
  • MRNA $129.39
  • NDSN $266.86
  • Technical
  • Relative Strength Index (RSI)
  • MRNA 67.06
  • NDSN 65.53
  • Support Level
  • MRNA $26.81
  • NDSN $213.11
  • Resistance Level
  • MRNA $28.24
  • NDSN $223.86
  • Average True Range (ATR)
  • MRNA 1.24
  • NDSN 4.27
  • MACD
  • MRNA 0.34
  • NDSN -0.04
  • Stochastic Oscillator
  • MRNA 93.38
  • NDSN 93.21

About MRNA Moderna Inc.

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

About NDSN Nordson Corporation

Nordson manufactures equipment (including pumps, valves, dispensers, applicators, filters, and pelletizers) used for dispensing adhesives, coatings, sealants, and other materials. The firm serves a diverse range of end markets including packaging, medical, electronics, and industrial. Nordson's business is organized into three segments: industrial precision solutions, medical and fluid solutions, and advanced technology solutions. The company generated approximately $2.7 billion in revenue in its fiscal 2024.

Share on Social Networks: